Journal of Virology & Antiviral ResearchISSN: 2324-8955

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study

Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study

Background: We previously reported response-guided therapy (RGT) of peginterferon (Peg-IFN)-2a with or without ribavirin (RBV) for chronic hepatitis C (CHC) of genotype 1b (a multicenter randomized trial, ReGIT-J study). Here, we performed a subgroup analysis of the ReGIT-J study according to age. Methods: The sustained virological response (SVR) rate and the treatment discontinuation rate were calculated in both groups. Results: In the elderly group (65 years, n=54), the SVR rate in the RGT group was higher than in the non- RGT group (50% [9/18] vs 36% [8/22], P=0.385). Similarly, in the control group (<65 years, n=132), the SVR rate in the RGT group was higher than in the non-RGT group (65% [31/48] vs 50% [27/54], P=0.138). In the elderly group, the discontinuation rate in the RGT group was almost significantly lower than in the non-RGT group (0% [0/18] vs 18% [4/22], P=0.057), whereas in the control group, the difference between the groups was not significant (4% [2/48] vs 13% [7/54], P=0.118). Furthermore, in all subgroup analyses, there was no significant difference between the elderly and control groups in terms of treatment response. Conclusion: Our proposed RGT was well tolerated in elderly CHC patients treated with Peg-IFN-2a with or without RBV.

Special Features

Full Text

View

Track Your Manuscript

Share This Page

Media Partners

Associations